Lupin’s investments in Research and Development (R&D) have helped us gain a leadership position in differentiated product introductions and become a formidable player in the generics space.
At Lupin, we are embracing advanced technologies, scientific breakthroughs and partnerships that enable us to advance research and development towards building a diversified portfolio and gain a leadership position in important new product introductions. Our Research & Development helps build a solid foundation as we progress to become a Complex Generics, Biosimilars and Specialty front runner.
Lupin has a solid team of 1,700 scientists and technologists employed at state-of-the-art facilities across the world. We are well on track to emerge as an innovation-led transnational pharmaceutical organisation providing affordable healthcare solutions with uncompromising quality. Within Europe, Nanomi, a Lupin business, leads the field in nanoparticle manufacture and complex injectable development.
Lupin’s research scientists have a proven track record of delivering high-quality technology-intensive products, Active Pharmaceutical Ingredients (APIs), formulations and newer dispensation forms.
LUP-CORP-005s DOP: October 2020
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.